Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Sequential monotherapy is recommended for anthracyclineand taxane-resistant metastatic breast cancer (MBC), but combination chemotherapy is considered in patients with visceral crisis. Cisplatin-doublet chemotherapy is a combination regimen for MBC, but prolonged treatment is challenging because of toxicity. We analyzed the role of single-agent maintenance chemotherapy after cisplatin-doublet chemotherapy for MBC. Methods: From January 2011 to December 2017, 96 anthracycline- and taxane- resistant MBC patients were retrospectively reviewed, and 49 patients with a sustained clinical benefit during the initial 6 cycles of cisplatin-doublet chemotherapy were enrolled for study. Patients were treated with gemcitabine-cisplatin (gemcitabine, 1,250 mg/m2, intravenously [IV], days 1 to 8; cisplatin 60 mg/m2, IV, day 1) or capecitabine-cisplatin (capecitabine 2,500 mg/m2, orally, days 1 to 14; cisplatin 60 mg/m2, IV, day 1) during the induction period. After 6 cycles, 16 patients were switched to single-maintenance treatment (gemcitabine or capecitabine) and the doublet regimen was continued in 24 patients. Survival outcomes (progression- free survival [PFS] and overall survival [OS]) were analyzed. Results: Among the 49 patients who showed a clinical benefit during cisplatin- doublet therapy, 24 were maintained on the doublet regimen, 16 were switched to single-maintenance treatment, and chemotherapy was suspended until disease progression in nine patients. The single-maintenance chemotherapy group showed superior survival than the chemotherapy holiday and doublet regimen groups (median PFS 15.43 months vs. 8.37 and 10.67 months, respectively, p = 0.008; median OS 43.67 months vs. 22.17 and 22.33 months, respectively, p = 0.014). Conclusions: Patients showing a clinical benefit during 6 cisplatin-doublet chemotherapy cycles may have a sustained survival benefit from single-maintenance chemotherapy.
Abstract
Background/Aims: Sequential monotherapy is recommended for anthracyclineand taxane-resistant metastatic breast cancer (MBC), but combination chemotherapy is considered in patients with visceral crisis. Cisplatin-doublet chemotherapy is a combination regimen for MBC, but prolonged treatment is challenging because of toxicity. We analyzed the role of single-agent maintenance chemotherapy after cisplatin-doublet chemotherapy for MBC. Methods: From January 2011 to December 2017, 96 anthracycline- and taxane- resistant MBC patients were retrospectively reviewed, and 49 patients with a sustained clinical benefit during the initial 6 cycles of cisplatin-doublet chemotherapy were enrolled for study. Patients were treated with gemcitabine-cisplatin (gemcitabine, 1,250 mg/m2, intravenously [IV], days 1 to 8; cisplatin 60 mg/m2, IV, day 1) or capecitabine-cisplatin (capecitabine 2,500 mg/m2, orally, days 1 to 14; cisplatin 60 mg/m2, IV, day 1) during the induction period. After 6 cycles, 16 patients were switched to single-maintenance treatment (gemcitabine or capecitabine) and the doublet regimen was continued in 24 patients. Survival outcomes (progression- free survival [PFS] and overall survival [OS]) were analyzed. Results: Among the 49 patients who showed a clinical benefit during cisplatin- doublet therapy, 24 were maintained on the doublet regimen, 16 were switched to single-maintenance treatment, and chemotherapy was suspended until disease progression in nine patients. The single-maintenance chemotherapy group showed superior survival than the chemotherapy holiday and doublet regimen groups (median PFS 15.43 months vs. 8.37 and 10.67 months, respectively, p = 0.008; median OS 43.67 months vs. 22.17 and 22.33 months, respectively, p = 0.014). Conclusions: Patients showing a clinical benefit during 6 cisplatin-doublet chemotherapy cycles may have a sustained survival benefit from single-maintenance chemotherapy.
참고문헌 (17)
- Harbeck N, "Breast cancer", Lancet, 389, pp.1134~1150 (2017)
- Cardoso F, "4th ESO-ESMO international consensus guidelines for advanced breast cancer(ABC 4)", Ann Oncol, 29, pp.1634~1657 (2018)
- Martin M, "Platinum compounds in the treatment of advanced breast cancer", Clin Breast Cancer, 2, pp.190~208 (2001)
- Hu XC, "Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer(CBCSG006) : a randomised, open-label, multicentre, phase 3 trial", Lancet Oncol, 16, pp.436~446 (2015)
- Stemmler HJ, "Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer", Br J Cancer, 104, pp.1071~1078 (2011)
- 김정환, "Phase II Study of Gemcitabine plus Cisplatin in Patients with Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer", Cancer Research and Treatment, 40(3), pp.101~105 (2008), 대한암학회
- Lee J, "Capecitabine and cisplatin(XP)combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer", PLoS One, 12, pp.e0171605~ (2017)
- Staudacher L, "Platinum-based chemotherapy in metastatic triple-negative breast cancer : the Institut Curie experience", Ann Oncol, 22, pp.848~856 (2011)
- Shamseddine AI, "Platinum-based compounds for the treatment of metastatic breast cancer", Chemotherapy, 57, pp.468~487 (2011)
- Li Q, "A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes", Cancer Biol Ther, 16, pp.1746~1753 (2015)
- Kohail H, "A phase 2 study of the combination of gemcitabine and cisplatin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines with", without taxanes, 2012, pp.5, 42~48
- Park YH, "Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy : KCSGBR07-02", J Clin Oncol, 31, pp.1732~1739 (2013)
- Paz-Ares LG, "PARAMOUNT : final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer", J Clin Oncol, 31, pp.2895~2902 (2013)
- Loibl S, "HER2-positive breast cancer", Lancet, 389, pp.2415~2429 (2017)
- Gerber DE, "Maintenance chemotherapy for advanced non-small-cell lung cancer : new life for an old idea", J Clin Oncol, 31, pp.1009~1020 (2013)
- Seo JH, "Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer", Cancer Chemother Pharmacol, 59, pp.269~274 (2007)
- Zhang J, "Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer", Int J Cancer, 136, pp.204~211 (2015)